alexa Squamous Cell Carcinoma in Bladder Extrophy : A Case Report and Literature Review | Open Access Journals
ISSN: 2165-7920
Journal of Clinical Case Reports
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Squamous Cell Carcinoma in Bladder Extrophy : A Case Report and Literature Review

Asmae Touil1*, Hasnaa Loughlimi1, Sarah El-Abbassi1, Hafsa Elouazzani2, Najat Mahassini2, Hanane El-Kacemi1, Kebdani Tayeb1 and Noureddine Benjaafar1

1Department of Radiation Oncology, National Institute of Oncology, Mohamed V University in Rabat, Morocco

2Department of Pathology, IbnSina hospital, Mohamed V University in Rabat, Morocco

*Corresponding Author:
Mbamalu ON
Discipline of Pharmacology, School of Pharmacy
University of the Western Cape Bellville 7535, South Africa
Tel: +27219593229/2190
Fax: +278615107002
E-mail: [email protected]

Received date: May 16, 2017; Accepted date: June 22, 2017; Published date: June 24, 2017

Citation: Touil A, Loughlimi H, El-Abbassi S, Elouazzani H, Mahassini N, et al. (2017) Squamous Cell Carcinoma in Bladder Extrophy : A Case Report and Literature Review. J Clin Case Rep 7:982. doi:10.4172/2165-7920.1000982

Copyright: © 2017 Touil A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Clinical Case Reports


Background: Bladder extrophy is a rare congenital anomaly, it is now well reconized that an exstrophy of the bladder is associated with an increased risk of bladder cancer.

Case presentation: We report the case of 34-year-old male with squamous cell carcinoma of an unreconstructed exstrophic bladder. Because of the locally advanced disease, he received neoadjuvant chemotherapy with favorable response. Then, he underwent a total cystectomy with uretero-intestinal anastamosis.

Results: The patient progressed three months after the surgery. Chemotherapy was established and he received 2 cycles, however, he died 2 months later.

Conclusion: Squamous cell carcinoma associated with bladder extrophy remains relatively high. These tumors tend to be aggressive, follow-up is mandatory in these cases.


Squamous Cell Carcinoma (SCC); Bladder extrophy


Bladder extrophy is a rare congenital anomaly with an incidence of about 1 in 50,000 newborns [1,2]. It’s a protrusion of the urinary bladder through a defect in the abdominal wall [3]. Bladder Exstrophy– Epispadias Complex (BEEC) describes a spectrum of birth defects involving failure of urogenital development during early gestation [4]. With the development of new repair techniques, the quality of life of patients has been greatly improved. However, it is now well recognized that exstrophy of the bladder is associated with an increased risk of bladder cancer [1]. Sixty percent of cancers in ectopic bladder occur during fourth and fifth decade of life, majority of them being adenocarcinoma (95%) [2]. We report here, a case of squamous cell carcinoma on a patient with neglected bladder extrophy.

Case Report

We report the case of a 34-year-old male patient, without medical history, who lived with an exstrophied bladder (exstrophy-epispadiasis complex). The patient noticed a progressive growth in his abdomen about 2-years prior to the presentation. By the time of diagnosis, it was ulcerated and surinfected. The examination of the lower abdomen revealed a classical exstrophy– epispadiasis complex in the suprapubic region of the anterior abdominal wall with noticeable growth in the bladder extrophy. A tumour measuring about 60 mm × 50 mm dominated the bladder area. The growth didn’t extend into the urethra and the scrotum was normal with normally descended testes. Rest of the systemic examination was within normal limits. Patient had no known comorbid illnesses. The lesion was biopsied and found to be invasive SCC (Figure 1). CT scan of the abdomen showed a classical Exstrophy-Epispadiasis complex with a mass in bladder exstrophy invading the skin and the subcutaneous fat tissue, measuring 63 mm. The mass caused an obstruction of the bilateral ureteric orifices resulting in bilateral hydrouretero-nephrosis, the right lumbar ureter measured 18 mm, remaining dilated until its delivery in the neo bladder, the same goes for the pelvic ureter measuring 20 mm. Many lymph nodes were involved: obturator, external iliacs, the largest one measuring 19 mm × 13 mm. Liver presented no lesions. Chest X-ray was normal.


Figure 1: Mucosa of bladder extrophy in squamous metaplagia.

The patient was planned for neoadjuvant chemotherapy and received three cycles with 5fluoro-uracil and Cisplatin. The reassessment showed a good local cutaneous response but no measurable tumour regression was shown in the CT scan. The patient was taken up for surgery. A wide excision of the tumour along with exstrophy-epispadiasis complex (entailing total cystectomy) was performed along with uretero-intestinal anastamosis using the Wallace method. The histopathology report showed a moderately differentiated squamous cell carcinoma (Figure 2) of size 58 mm × 55 mm invading the entire bladder wall (Figure 3), prostate (Figure 4), and the skin (Figure 5). The ureteral and uretral margin was not seen. Lymphovascular and perineural invasions were found. Three months after the surgery, a CT scan showed a local tumor progression. After the multidisciplinary consultation meeting: chemotherapy regimen 5FU-Cisplatin was established. The patient received 2 cycles of chemotherapy, however, the patient died 2 months later.


Figure 2: SCC: tumor’s proliferation consists of nests and cords of tumoral cells, showing signs of keratinization with union bridge and horned globes.


Figure 3: SCC infiltrating the bladder wall, the mucosa apears in the right of the image.


Figure 4: SCC infiltrating the prostate, the prostatic channels are crushed in the right of the image.


Figure 5: SCC invading the skin.


Bladder extrophy is a rare congenital anomaly [4,5]. Bladder exstrophy–epispadias complex (BEEC) describes a spectrum of birth defects involving failure of urogenital development during early gestation [2,4,5]. It’s incidence is estimated at 2.7 per 100,000 live births. It’s etiology is attributed to abnormal partitioning of the cloacal membrane, which prevents migration of mesenchymal tissue for proper lower abdominal wall development [4]. It is more commonly diagnosed in males (Male: female - 5:1 to 6:1) [1]. The malignant potential of exstrophied bladder mucosa is well known [1,2], 95% are adenocarcinoma; and 3% to 5% are squamous cell carcinomas [1,2,5-7]. Majority (60%) of the malignant tumours in ectopic bladders occur during the fourth and fifth decade of life and out of the remaining (about 20%) occur after 60 years and before 40 years. [1,2,5,6].

Chronic irritation and infection leading to metaplastic transformation of the urothelium resulting in malignant changes is the most likely possibility [1,2,4,7]. Malignant degeneration of embryonic rests of gastrointestinal tissue can give rise to adenocarcinoma. It is also suggested that adenocarcinoma in exstrophic bladder originates from the colonic epithelium covering the mucosa of the organ [2].

Currently, exstrophy of the bladder can be diagnosed antenatally with the use of high-resolution real-time ultrasound [1]. With advances in pediatric medicine and reconstructive surgery, the morbidity and mortality of this disease has decreased drastically. In the developing world, however, one may come across these cases in older patients often because of a delay in seeking medical advice [1]. This was the case with our patient. The current golden standard for managing bladder exstrophies is surgical reconstruction [2]. Urinary diversion with removal of the bladder plate, along-with ureterosigmoidostomy, is an alternative, but carries a higher risk of malignancy [4]. The treatment of squamous cell carcinoma of the bladder remains similar to the treatment of urothelial cell carcinoma [5]. Meanwhile, the golden standard of treatment of squamous cell carcinoma of the bladder is radical cystectomy, with no established guidelines for any adjuvant or neoadjuvant therapy. Radiation therapy is offered to inoperable cases or those who refuse surgery [1,2].

There are no specific guidelines for follow-up in cases of squamous cell carcinoma. The guidelines for follow-up of bladder cancer in general are applied also for patients with squamous cell carcinoma [1].

The prognosis of SCC of the bladder is poor due to its advanced stage at diagnosis [1,2,5]. Kassouf et al. reported a median recurrencefree survival of 5.1 months [1,5]. Till date, no data is available to assess the differential prognosis of SCC and adenocarcinoma with regard to the exstrophy patients as most data is case reports [5].

Despite bladder closure or diversion surgery within the first few years of life, patients with exstrophy have an almost 700-fold greater incidence of carcinoma of the bladder than the age-matched general population. Early cystectomy is not protective [8]. Currently, no guidelines for screening of bladder carcinoma in patients with history of exstrophy with cystectomy have been established [4].


The development of reconstruction techniques improved the quality of life of patients with bladder extrophy, however the risk of malignant degeneration remains high. Squamous cell carcinoma remains a rare entity. These tumors tend to be aggressive, good follow-up is highly recommended in these patients.

Consent for Publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Competing Interests

The authors declare that they have no competing interests.


Special thanks are due to the Faculty of Medicine and Pharmacy of Rabat; the source(s) of funding for all authors


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • Global Experts Meeting on Case Reports
    Osaka, Japan October 09-11, 2017
  • 6th Global Experts Meeting on Medical Case Reports
    October 16-18, 2017 San Francisco, California, USA

Article Usage

  • Total views: 224
  • [From(publication date):
    June-2017 - Sep 25, 2017]
  • Breakdown by view type
  • HTML page views : 195
  • PDF downloads :29

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version